ChemRegen Inc

Biotech · Private

Small molecule drug candidates targeting non-opioid receptors for pain management and opioid addiction treatment

chemregen.com →
Grants
$614K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Non-Toxic Small Molecule for Inhibition of Prostate Cancer$214,649
Federal grantDepartment of Health and Human Services · Phase I · iPSC-derived human neurons and OUD medications development$399,536
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2025Sentonix, Inc.—$18M
2026NXT BIOLOGICS, INC.——
2027ADVANCED MOLECULAR HEALIX INC.——
2028ChemRegen Inc——
2029LIFORDI IMMUNOTHERAPEUTICS, INC.——
2030PROGENITOR INC.——
2031YALI BIOSCIENCES INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.